Abstract
Mast cells are important in the development of allergic and anaphylactic reactions, but also in acquired and innate immunity. There is also increasing evidence that mast cells participate in inflammatory diseases, where they can be activated by non-allergic triggers, such as neuropeptides and cytokines, often having synergistic effects as in the case of substance P (SP) and IL-33. Secretion of vasoactive mediators, cytokines and proteinases contribute to the development of coronary artery disease (CAD), as well as to dietinduced obesity and the metabolic syndrome. Mast cells may be able to orchestrate such different biological processes through their ability to release pro-inflammatory mediators selectively without the degranulation typical of allergic reactions. Recent evidence suggests that mitochondrial uncoupling protein 2 (UCP2) and mitochondrial translocation regulate mast cell degranulation, but not selective mediator release. Better understanding of these two processes and how mast cells exert both immunostimulatory and immunosuppressive actions could lead to the development of inhibitors of release of specific mediators with novel therapeutic applications.
Keywords: Coronary artery disease, diabetes, inflammation, mast cells, mitochondria secretion
Current Pharmaceutical Design
Title:Mast Cells in Allergic and Inflammatory Diseases
Volume: 18 Issue: 16
Author(s): Nikolaos Sismanopoulos, Danae-Anastasia Delivanis, Konstantinos-Dionysios Alysandratos, Asimenia Angelidou, Anastasia Therianou, Dimitrios Kalogeromitros and Theoharis C. Theoharides
Affiliation:
Keywords: Coronary artery disease, diabetes, inflammation, mast cells, mitochondria secretion
Abstract: Mast cells are important in the development of allergic and anaphylactic reactions, but also in acquired and innate immunity. There is also increasing evidence that mast cells participate in inflammatory diseases, where they can be activated by non-allergic triggers, such as neuropeptides and cytokines, often having synergistic effects as in the case of substance P (SP) and IL-33. Secretion of vasoactive mediators, cytokines and proteinases contribute to the development of coronary artery disease (CAD), as well as to dietinduced obesity and the metabolic syndrome. Mast cells may be able to orchestrate such different biological processes through their ability to release pro-inflammatory mediators selectively without the degranulation typical of allergic reactions. Recent evidence suggests that mitochondrial uncoupling protein 2 (UCP2) and mitochondrial translocation regulate mast cell degranulation, but not selective mediator release. Better understanding of these two processes and how mast cells exert both immunostimulatory and immunosuppressive actions could lead to the development of inhibitors of release of specific mediators with novel therapeutic applications.
Export Options
About this article
Cite this article as:
Sismanopoulos Nikolaos, Delivanis Danae-Anastasia, Alysandratos Konstantinos-Dionysios, Angelidou Asimenia, Therianou Anastasia, Kalogeromitros Dimitrios and C. Theoharides Theoharis, Mast Cells in Allergic and Inflammatory Diseases, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800165997
DOI https://dx.doi.org/10.2174/138161212800165997 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis
Current Drug Targets Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges
Current Pharmaceutical Design Two Age-Related Accumulation Profiles of Toxic Metals
Current Aging Science Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design